Test PROCYP
Lack of assurance of sterility for injectables and solutions intended to be sterile.
18,003 recalls, newest first
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Marketed Without An Approved NDA/ANDA: FDA analysis found this product to be tainted with undeclared sildenafil and tadalafil, two FDA approved drugs for the treatment of male erectile dysfunction, making this an unapproved drug for which safety and efficacy have not been established and, therefore, subject to recall.
Failed Impurities/Degradation Specifications; 18 month long term stability study (manufacturer)
Failed Impurities/Degradation Specifications: Unknown impurity above specification limits.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.
Lack of sterility assurance.